Alger Life Sciences Innovation Fund LP is a hedge fund based in New York, New York. According to its most recent Form D, filed Apr 10, 2026, the fund has sold $30,286,264 of interests to 13 investors since its first sale in May 2022. The minimum investment it accepts from an outside investor is $500,000. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Based on its first sale date and the amount raised, HedgeMountain classifies it as an emerging manager. Related persons named in the filing include Daniel Chung; Alger Alternative Holdings II, LLC; Hal Liebes.
Performance
No verified returns have been reported for this fund. Hedge fund returns are not part of SEC filings; managers report them to HedgeMountain directly.
Is this your fund? Report your monthly returns · How performance works
- Total raised
- $30,286,264Cumulative sales reported on Form D
- Investors
- 13
- First sale
- May 20, 2022
- Minimum investment
- $500,000
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Daniel Chung; Alger Alternative Holdings II, LLC; Hal Liebes
- Latest Form D
- Apr 10, 2026
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and HedgeMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures
Size compared with every hedge fund
Raised more than 35% of the 2,479 hedge funds based in New York, and more than 37% of all 10,157 that report sales.